DE69506686D1 - Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase - Google Patents

Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase

Info

Publication number
DE69506686D1
DE69506686D1 DE69506686T DE69506686T DE69506686D1 DE 69506686 D1 DE69506686 D1 DE 69506686D1 DE 69506686 T DE69506686 T DE 69506686T DE 69506686 T DE69506686 T DE 69506686T DE 69506686 D1 DE69506686 D1 DE 69506686D1
Authority
DE
Germany
Prior art keywords
bis
amidinobenzidazoles
medicine
producing
retroviral integrase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69506686T
Other languages
English (en)
Other versions
DE69506686T2 (de
Inventor
Christine C Dykstra
Ronald I Swanstrom
Richard R Tidwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
University of North Carolina System
Original Assignee
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Publication of DE69506686D1 publication Critical patent/DE69506686D1/de
Application granted granted Critical
Publication of DE69506686T2 publication Critical patent/DE69506686T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thin Film Transistor (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Recrystallisation Techniques (AREA)
DE69506686T 1994-01-20 1995-01-18 Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase Expired - Fee Related DE69506686T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/185,079 US6815461B1 (en) 1994-01-20 1994-01-20 Method of inhibiting retroviral integrase
PCT/US1995/000504 WO1995019772A1 (en) 1994-01-20 1995-01-18 Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase

Publications (2)

Publication Number Publication Date
DE69506686D1 true DE69506686D1 (de) 1999-01-28
DE69506686T2 DE69506686T2 (de) 1999-07-22

Family

ID=22679488

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69506686T Expired - Fee Related DE69506686T2 (de) 1994-01-20 1995-01-18 Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase

Country Status (11)

Country Link
US (1) US6815461B1 (de)
EP (1) EP0739202B1 (de)
JP (1) JP3306830B2 (de)
AT (1) ATE174508T1 (de)
AU (1) AU675386B2 (de)
BR (1) BR9506552A (de)
CA (1) CA2179015C (de)
DE (1) DE69506686T2 (de)
ES (1) ES2128043T3 (de)
NZ (2) NZ279619A (de)
WO (1) WO1995019772A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
US5693515A (en) * 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors
US6369235B1 (en) 1997-02-25 2002-04-09 The United States Of America As Represented By The Department Of Health And Human Services Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
EP1019382A1 (de) * 1997-04-07 2000-07-19 Axys Pharmaceuticals, Inc. Milde flüssige reinigungszusammensetzungen in form einer mikroemulsion
FR2766822B1 (fr) * 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999026933A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
HUP0101137A3 (en) 1998-04-10 2003-03-28 Japan Tobacco Inc Anticoagulant amidines and their pharmaceutical use
DK1176193T3 (da) * 1999-05-13 2012-09-10 Japan Science & Tech Agency Hæmmere af virusinfektion, som angriber den n-terminale region af integrase
CA2375843A1 (en) * 1999-06-04 2000-12-14 Qi Zhao Compositions and methods for inhibiting cell death
US6774144B1 (en) 1999-11-01 2004-08-10 The University Of North Carolina At Chapel Hill Methods and formulations for the treatment of infectious bursal disease in avian subjects
AU1450401A (en) * 1999-11-01 2001-05-14 Auburn University Methods and formulations for the treatment of infectious bursal disease in avian subjects
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2008089125A2 (en) * 2007-01-15 2008-07-24 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases Antiviral compounds and methods of using thereof
US8207209B2 (en) * 2007-10-24 2012-06-26 Functional Genetics, Inc. Methods of inhibiting viral infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA708089B (en) * 1969-12-29 1971-08-25 Abbott Lab Bis-benzimidazole derivatives
US4619942A (en) * 1982-04-08 1986-10-28 University Of North Carolina Inhibition of Respiratory Syncytial virus-induced cell fusion by amidino compounds
US4933347A (en) 1988-10-25 1990-06-12 University Of North Carolina At Chapel Hill Diamidines and bis(imidazolines) for the treatment of and prophylaxis against pneumocystis carinii pneumonia
US4963589A (en) 1988-10-25 1990-10-16 The University Of North Carolina At Chapel Hill Methods for treating Giardia lamblia
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
HUT71345A (en) 1993-09-22 1995-11-28 Wellcome Found Bis(amidinobenzimidazolyl)alkanes and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ATE174508T1 (de) 1999-01-15
AU1679895A (en) 1995-08-08
NZ279619A (en) 1999-09-29
BR9506552A (pt) 1997-10-28
WO1995019772A1 (en) 1995-07-27
CA2179015C (en) 2003-06-24
AU675386B2 (en) 1997-01-30
US6815461B1 (en) 2004-11-09
CA2179015A1 (en) 1995-07-27
DE69506686T2 (de) 1999-07-22
JP3306830B2 (ja) 2002-07-24
EP0739202A1 (de) 1996-10-30
EP0739202B1 (de) 1998-12-16
ES2128043T3 (es) 1999-05-01
NZ335226A (en) 2000-11-24
JPH09508369A (ja) 1997-08-26

Similar Documents

Publication Publication Date Title
DE69506686T2 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94044454A (ru) Ингибитор аутоимунных заболеваний
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE69227583T2 (de) Arylmorpholine, herstellung und verwendung
ATE232387T1 (de) Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
CA2137961A1 (en) Cyclic depsipeptides having 18 ring atoms, and their use for combating endoparasites
NZ308260A (en) Use of 5-(substituted biphenyl)-tetrazole derivatives to treat multiple system organ failure
ATE216237T1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
ES2041679T3 (es) Compuestos analgesicos de octohidroindolizinas 5-substituidas y productos intermedios 7-ceto.
KR950016720A (ko) 아밀로이드 단백질의 효과를 저해하는 방법
ES8802505A1 (es) Procedimiento para preparar acidos hexenoicos.
ATE216235T1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
DE69905144D1 (de) N,N'-Diacylthiocystine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee